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Abstract
This study was designed to investigate the influence of TSER and MTHFR polymorphisms on the 
clinical  outcomes  of  patients  with  colorectal  cancer  receiving  5-FU-based  chemotherapy. 
Genomic DNA was isolated from 103 frozen or  paraffin-embedded tissues of colorectal cancer 
patients. The genotypes of two common polymorphisms were determined by PCR-RFLP. Patient 
prognoses  were  compared  with  genotype  groups  and  analyzed  according  to  tumor  location. 
Polymorphisms  of  TSER and  MTHFR 677C>T  were  not  significantly  associated  with 
clinicopathological  factors.  There  were  no  differences  in  prognosis  between  genotypes  or 
functional  groups when the  TSER and  MTHFR groups were considered separately.  However, 
analysis  of  combined  genotypes  of  the  TSER and the  MTHFR 677C>T polymorphisms were 
associated  with  the  survival  rate  of  colorectal  cancer  patients  who  received  5-FU-based 
chemotherapy (p=0.028).  Prognosis  of  colorectal  cancer  patients  was  significantly  different 
between proximal colon and distal colon cancers (p=0.002).  However, prognosis did not receive 
any effect of the combined genotype when analyzed according to tumor location, such as proximal 
and distal colon cancer. The combined TSER and MTHFR 677C>T genotypes can be prognostic 
factors in colorectal cancer, where gene-gene interactions between the genotypes may occur. 
Keywords: Methylenetetrahydrofolate reductase (MTHFR); thymidylate synthase enhance region 
(TSER); colorectal cancer, prognosis; polymorphism
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Introduction
Despite advancements in the diagnosis and early treatment of colorectal cancer, the need for better 
tools to predict  outcome and response to treatment is well recognized.  Pharmacogenetics has 
attracted considerable attention in the study of cancer chemotherapy treatment in recent years. 
5-FU has been used in the treatment of cancers such as colorectal cancer, breast cancer and head 
and neck cancer for about 50 years. The major target of 5-FU is thymidylate synthase (TS), which 
catalyzes the transformation dUMP into dTMP, an important process in DNA synthesis and repair. 
However, objective tumor responses are observed in only 15% to 20% of patients treated with 5-
FU.1 One  current  strategy to improve the  effectiveness  of  chemotherapy for the  treatment  of 
advanced colorectal cancer is based on the ability of reducing folate to modulate the cytotoxic 
effect  of  5-FU.  Experimental  studies have established that  optimal TS inhibition requires the 
stabilization  of  ternary  complex  between TSER,  fluorodeoxyuridinemonophosphate  (FdUMP) 
converted from 5-FU, and 5,10- methylenetetrahydrofolate (CH2FH4).2,3     Accordingly, clinical 
studies have demonstrated that higher chemotherapy efficacy of 5-FU is associated with folic acid, 
a precursor of 5,10-methylenetetrahydrofolate.4,5 
Methylenetetrahydrofolate  reductase  (MTHFR)  catalyzes  the  conversion  of  5,10-methylene-
tetrahydrofolate (5,10-CH2FH4) to 5’-methyltetrahydrofolate (5-CH3FH4). MTHFR plays a central 
role in folate metabolism, regulating the flow of folate between these two important pathways: 
production of thymidylate and purines for DNA synthesis and supply of methyl groups for the 
synthesis of methionine and DNA methylation. 6 Two common polymorphisms of the  MTHFR 
gene have been described, and the 677C>T polymorphism has been reported to affect enzymatic 
activity. 7 In vitro analysis of MTHFR activity indicates that the MTHFR 677T allele variant has an 
enzymatic activity of 30% compared with the MTHFR 677CC genotype.
Decreased  enzymatic  activity  of  MTHFR  in MTHFR 677TT  homozygotes  may  lead  to 
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accumulation  of  5,10-methylenetetrahydrofolate  and  thereby  improve  the  efficacy  of  5’-FU 
treatment  through  stabilization  of  the  ternary  complex. 8 We hypothesized  that  the  variable 
number  of  tandem  repeat  (VNTR)  of  the  TSER gene  together  with  MTHFR 677C>T 
polymorphism could alter drug activity and predict drug toxicity or efficacy.
In  this  study,  we  investigated  the  associations  between  two  common  polymorphisms  and 
prognosis  in  103  colorectal  cancer  patients  receiving  5-FU chemotherapy.  We also  evaluated 
whether combined genotypes of the MTHFR 677C>T and TSER polymorphisms affect colorectal 
cancer patient survival. 
Results
TSER and MTHFR genotype distribution 
We examined the TSER and MTHFR 677C>T polymorphisms in  35 consecutive patients with 
proximal colorectal cancer and 68 consecutive patients with distal colorectal cancer. The clinical 
and pathological features of the colorectal cancer treated by surgery and adjuvant chemotherapy 
are shown in Table 1. There were no associations between the MTHFR 677C>T genotypes and 
clinicopathological factors,
 i.e., age, gender, pathological stage, tumor location. However, there 
was a significant difference between TSER genotypes by pathological stage (p=0.027; Table 2). 
Distribution of TSER genotypes in metastatic biopsies was 68.0% 3R3R type, 28.2% 2R3R type 
and 3.9% 2R2R type, and that of MTHFR 677C>T genotypes was 35.0% 677CC, 56.3% 677CT 
and  8.7%  677TT  type.  The  distribution  of  TSER  and  MTHFR  677C>T  genotypes  was  in 
agreement with the Hardy-Weinberg equilibrium. 
Prognostic significance of TSER and MTHFR genotypes
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We investigated the associations of the TSER and MTHFR genotypes with prognosis. The TSER 
and the MTHFR genotypes were each stratified into two groups because the statistical power was 
insufficient for analysis with more than two genotype groups. The TSER functional groups were 
classified as 2R(-) (3R3R) and 2R(+) (2R3R and 2R2R). The MTHFR 677C>T genotypes were 
classified as 677CC vs. 677CT and 677TT.
There were no significant relationships between overall prognosis and the genotype groups 
when all patients were included in the analysis (Figs. 1a and 1b). Thus, the prognostic significance 
of  the  combined  genotypes  was  further  evaluated  (Fig.  1c).  The  combined  genotypes  were 
classified into low-risk type (having two or less risk alleles) and high-risk type (having three or 
more risk alleles): low-risk type (3R3R+ 677CC, 2R3R+677CC, 2R2R+677CC, 2R3R+677CT, 
2R2R+677CT, 2R2R+677TT), high-risk type (3R3R+677CT, 3R3R+677TT, 2R3R+677TT). There 
was  a  significant  correlation  with  prognosis  in  the  combined  TSER and  MTHFR 677C>T 
genotypes (P=0.028).
When we analyzed survival according to the colorectal cancer sub-site,  there was also a 
significant  difference  between  proximal  colon  and  distal  colon  cancers  (P=0.002)  (Fig.  2a). 
However, in patients with proximal colon or distal colon cancers, the difference in survival rates 
between combined  TSER and  MTHFR 677C>T genotypes did not reach statistical significance 
(proximal colon P=0.558, Fig. 2b; distal colon P=0.058, Fig. 2c).
Discussion
Gene polymorphisms could be an important predictive factor in the treatment of colorectal cancer 
with  fluoropyrimidine-based  chemotherapy.  Several  studies  have  suggested  that  TSER 
polymorphisms influence 5-FU sensitivity  in vitro and in vivo.  The human TS promoter gene is 
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polymorphic with either double- or triple-tandem repeats of a 28-bp sequence downstream of the 
cap site in the 5’-terminal regulatory region.9 In vitro studies have shown that the TSER gene with 
triple-tandem repeats has 2.6-times higher activity than that with double-tandem repeats.14 TS 
level in tumor tissue may also be important because high expression of the TS protein and TSER 
mRNA  has been associated with resistance to 5-FU-based treatment, leading to poor survival 
outcomes in colorectal cancer.11-13 Pullarkat et al.14  reported that patients with the 2R2R  TSER 
polymorphism had a higher response rate than patients with 2R3R and 3R3R. Also, the 3R3R 
TSER gene polymorphism was associated  with  worse  prognosis  in  colorectal  cancer  patients 
receiving 5-FU-based chemotherapy than 2R2R and 2R3R,15; however, differing results have also 
been reported.16  
Other data have suggested that the MTHFR 677C>T polymorphism is also important for the 
effect of 5-FU-based chemotherapy. Decreased activity in MTHFR 677T allele carriers increases 
the availability of 5,10-methylene THF, which is a cofactor for 5-fluorouracil inhibition of TS. An 
in vitro study by Sohn KJ et al.17  suggested that cells expressing the mutant  677T MTHFR had 
decreased MTHFR activity, thermolability, and increased thymidylate synthase activity compared 
with cells expressing the wild-type MTHFR. The MTHFR 677T mutation also exhibited increased 
chemosensitivity of colon and breast cancers to 5-FU. In a large case-control study nested within a 
multiethnic cohort, they found an inverse association of the MTHFR 677TT genotype with risk of 
colorectal cancer. The MTHFR 677T allele had 23% reduced risk of colorectal cancer.18
In this study, we did not observe a significant effect of the TSER and the MTHFR 677C>T 
polymorphisms on the survival rate of colorectal cancer patients receiving 5-FU chemotherapy. 
Also, we did not find a significant relationship of each polymorphism and prognosis according to 
pathologic stage (data not shown).
The  TSER 2R(+) variants appeared to have better prognosis than  TSER 2R(-) variants, but 
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there was no significant difference in the pathologic stage.  However, we observed  a significant 
correlation with prognosis in combined  TSER and  MTHFR 677C>T genotypes. High-risk type 
was associated with worse prognosis of colorectal cancer receiving 5-FU-based chemotherapy. 
Mutation of important genes such as TSER and MTHFR does not have good effects on survival 
and inhibition of tumorigenesis even if the MTHFR 677T allele has a synergistic effect on 5-FU-
based therapy. 
We hypothesized that the chemotherapy effect would differ according to the tumor location 
in colorectal cancer. Colorectal cancers are divided according to the location of the cancer, such as 
the proximal and distal colon. Several studies provide evidence that epigenetic mechanisms such 
as  gene  methylation  play  a  differential  role  in  proximal  versus  distal  colon  carcinogenesis. 
Proximal colon cancer has been associated with hypermethylation of genes involved in mismatch 
repair, such as hMLH1, or in cell cycle control, such as p16INK4 and p14. Conversely, distal colon 
cancers have been associated with chromosomal instability by hypomethylation. 
Thus, the tumorigenesis mechanism differs according to the tumor location in colorectal 
cancer; therefore, we believe that the treatment methods of these cancers should also be different. 
Wolmark et al.19 determined the prognostic significance of tumor location and showed that tumor 
location was a strong prognostic determinant and that lesions located in the distal colon showed 
better survival than those in the proximal colon. Several other studies have also suggested that 
patients with distal  colon cancer  exhibit  better  survival  rates  than those with proximal colon 
cancer.20,21 However, these studies included cohorts that did not undergo chemotherapy treatment. 
However, our results were opposite to this.  When we analyzed survival according to the tumor 
location of colorectal  cancers,  proximal colon cancers had significantly better  prognosis  than 
distal colon cancers. 
Elsaleh et al.22 also reported that the presence of microsatellite instability in the proximal 
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colon  carcinoma  group  was  associated  with  significantly  improved  prognosis  and  may  also 
increase  the  likelihood  of  survival  after  chemotherapy.  The  main  cause  of  proximal  cancer 
associated  with  hypermethylation  was  frequent  methylation  of  CpG islands  in  the  promoter 
regions of repair genes. Whether this is associated with good response to chemotherapy in vivo 
because of deficiencies in DNA repair or because it is linked to the methylator phenotype remains 
unclear. Indeed, the methylator phenotype might prove to be an even stronger predictive factor for 
the response of colorectal cancers to chemotherapy.23, 24  
In the present study, we found that proximal colon cancer patients had a better prognosis than 
distal colon cancer patients through 5-FU chemotherapy. We also found that  high-risk type was 
associated with worse  prognosis  of  colorectal  cancer  receiving  5-FU-based chemotherapy. In 
conclusion, we suggest that chemotherapeutic treatment of colorectal cancer must differ according 
to the location of tumorigenesis and the combined genotypes of MTHFR and TSER. 
Patients and Methods
Patients and DNA isolation
We enrolled 103 colorectal cancer (CLC) patients (mean age±SD, 58.58±14.22; 35 proximal and 
68 distal CLC) diagnosed at Bundang CHA General Hospital, CHA University, Seongnam, South 
Korea. All of the patients were Korean and 103 consecutive patients with stage II, III and IV CLC 
were examined in this study: 43 patients with stage II, 41 patients with stage III and 19 patients 
with stage IV (Supplement Table 1).  All  patients completed scheduled postoperative adjuvant 
chemotherapy.  Specimens  were  taken  from  frozen  or  paraffin-embedded  tissues  by 
phenol/chloroform extraction methods and the quality was adequate. Paraffin was removed with 
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xylene at 50  overnight and the products were treated with 10% SDS and proteinase K. 
Genotyping of the VNTR in the thymidylate synthase enhancer region
TSER 28-bp tandem repeat number was investigated by PCR using forward primer 5’-GTG GCT 
CCT GCG TTT CCC CC-3’ and reverse primer 5’-GCT CCG AGC CGG CCA CAG GCA TGG 
CGC GG-3’ as described previously.25 PCR was performed using the PCR premix kit (HotStart 
PCR Premix, Bioneer, Korea) in a 20 l volume, and 0.5 mol of each primer was used. 
Amplified fragments were confirmed on a 3% agarose gel by electrophoresis. TSER 2R or 3R 
polymorphism was genotyped according to the size of the amplified fragment: 2R corresponded to 
220 bp and 3R corresponded to 248 bp.
Genotyping of the MTHFR 677C>T
The MTHFR genotype was examined using the PCR-RFLP method. DNA fragment containing 
MTHFR 677C>T (Ala to Val) was amplified with a GeneAmp PCR machine (Perkin Elmer 2400), 
forward primer, 5’-TGA AGG AGA AGG TGT CTG CGG GA-3’ and reverse primer, 5’-AGG 
ACG GTG CGG TGA GAG TG.-3’. MTHFR 677C>T genotypes were identified as described in 
Kim et al.26
Statistical analyses
Categorical data were analyzed using Chi-square and ANOVA tests. Significance was set at the 
0.05  level.  Survival  curves  were  generated  using  the  Kaplan-Meier  method.27 The  log-rank 
statistic was used to compare survival distributions.28 All calculations were done with GraphPad 
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Prism 4.0 (GraphPad Software, Inc., USA).
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Figure legends
Figure 1. Survival analysis of  colorectal cancer patients (n=103). Shown are the Kaplan-Meier 
overall  survival  curves.  (a)  Overall  survival  rate  according  to  the  TSER polymorphism.  (b) 
Overall survival rate according to the MTHFR polymorphism. (c) The survival curves by combine 
genotypes  of  MTHFR and  TSER polymorphism  (p=0.028)  (low  risk  type,  3R3R+677CC, 
2R3R+677CC,  2R2R+677CC,  2R3R+677CT, 2R2R+677CT, 2R2R+677TT vs.  high  risk  type, 
3R3R+677CT, 3R3R+677TT, 2R3R+677TT).
Figure 2. (a) Survival rate according to the tumor location of colorectal cancer; proximal colon 
and distal colon (p=0.002). The survival curves by combine genotypes of  MTHFR 677C>T and 
TSER polymorphism (b) in proximal colon and (c) in distal colon (low risk type, 3R3R+677CC, 
2R3R+677CC,  2R2R+677CC,  2R3R+677CT, 2R2R+677CT, 2R2R+677TT vs.  high  risk  type, 
3R3R+677CT, 3R3R+677TT, 2R3R+ 677TT).
Figure 3. Survival analysis according to gender of colorectal cancer patients; The survival curves 
by combine genotypes of  MTHFR 677C>T and  TSER polymorphism (a) in male patients with 
colorectal cancer and (b) in female patients with colorectal cancer (low risk type, 3R3R+677CC, 
2R3R+677CC,  2R2R+677CC,  2R3R+677CT, 2R2R+677CT, 2R2R+677TT vs.  high  risk  type, 
3R3R+677CT, 3R3R+677TT, 2R3R+ 677TT).
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Table 1 The clinicopathological feature in proximal and distal colorectal cancer (CLC)
Characteristic Total CLC Proximal CLC Distal CLC p
Age (n)a 56.97 ± 13.35 (103) 55.71 ± 14.43 (35) 57.62 ± 12.83 (68) 0.496
Male (%) 49 (47.6) 13 (37.1) 36 (52.9) 0.128
Stage (%)
II 43 (41.7) 18 (51.4) 25 (36.8)
III 41 (39.8) 11 (31.4) 30 (44.1)
IV 19 (18.4) 6 (17.2) 13 (19.1) 0.337
Values are mean ±SD or n (%) of participants except where indicated otherwise.  P-values are Chi-square 
test for categorical data, and two sample t-test for the continuous data in proximal CLC versus distal CLC.
a One-way ANOVA test
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Table 2 Characteristics of patients according to MTHFR 677C>T and TSER genotypes
TSER MTHFR 677C>T
Characteristics 3R3R 2R3R 2R2R p 677CC 677CT 677TT p
Total (%) 70 (68.0) 29 (28.2) 4 (3.9) 36 (35.0) 58 (56.3) 9 (8.7)
Gender (%)b
Male 40 (75.5) 10 (18.9) 3 (5.7) 21 (39.6) 26 (49.1) 6 (11.3)
Female 30 (60.0) 19 (38.0) 1 (2.0) 0.077 15 (30.0) 32 (64.0) 3 (6.0) 0.282 
Stage (%)b
II 28 (65.1) 14 (32.6) 1 (2.3) 16 (37.2) 26 (60.5) 1 (2.3)
III 25 (61.0) 15 (36.6) 1 (2.4) 16 (39.0) 21 (51.2) 4 (9.8)
IV 17 (89.5) 0 (0.0) 2 (10.5) 0.027 4 (21.1) 11 (57.9) 4 (21.1) 0.136 
Location (%)b
Proximal 25 (71.4) 7 (20.0) 3 (8.6) 16 (45.7) 17 (48.6) 2 (5.7)
Distal 45 (66.2) 22 (32.4) 1 (1.5) 0.114 20 (29.4) 41 (60.3) 7 (10.3) 0.237 
MTHFR, methylenetetrahydrofolate reductase; TSER, thymidylate synthase enhancer region.
b Chi-square test
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Supplement Table 1 Characteristics of patients group according to gender, cancer location and risk type
Low risk type High risk type Male Female
Stages n (%) (n, %) (n, %) (n, %) (n, %)
Proximal II 18 (51.4) 11 (55.0) 7 (46.7) 7 (53.8) 11 (50.0)
III 11 (31.4) 6 (30.0) 5 (33.3) 5 (38.5) 6 (27.3)
IV 6 (17.1) 3 (15.0) 3 (20.0) 1 (7.7) 5 (22.7)
35 20 (100.0) 15 (100.0) 13 (100.0) 22 (100.0)
Distal II 25 (36.8) 15 (48.4) 10 (27.1) 11 (30.6) 14 (43.8)
III 30 (44.1) 14 (45.2) 16 (43.2) 18 (50.0) 12 (37.5)
IV 13 (19.1) 2 (6.4) 11 (27.7) 7 (19.4) 6 (18.7)
68 31 (100.0) 37 (100.0) 36 (100.0) 32 (100.0)
Male II 18 (36.8) 11 (50.0) 7 (25.9) _ _
III 23 (46.9) 11 (50.0) 12 (44.5) _ _
IV 8 (16.3) 0 (0) 8 (29.6) _ _
49 22 (100.0) 27 (100.0) _ _
Female II 25 (46.3) 15 (51.7) 10 (40.0) _ _
III 18 (33.3) 9 (31.0) 9 (36.0) _ _
IV 11 (20.4) 5 (17.3) 6 (24.0) _ _
54 29 (100.0) 25 (100.0) _ _
Low risk typea II 26 (51.0) _ _ 11 (50.0) 15 (51.7)
III 20 (39.2) _ _ 11 (50.0) 9 (31.0)
IV 5 (9.8) _ _ 0 (0) 5 (17.3)
51 _ _ 22 (100.0) 29 (100.0)
High risk typeb II 17 (32.7) _ _ 7 (25.9) 10 (40.0)
III 21 (40.4) _ _ 12 (44.5) 9 (36.0)
IV 14 (26.9) _ _ 8 (29.6) 6 (24.0)
52 _ _ 27 (100.0) 25 (100.0)
aLow  risk  type:  3R3R+677CC,  2R3R+677CC,  2R2R+677CC,  2R3R+677CT,  2R2R+677CT,  2R2R+ 
677TT.  
bHigh risk type: 3R3R+677CT, 3R3R+677TT, 2R3R+ 677TT.
21
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
09
.3
74
1.
1 
: P
os
te
d 
9 
Se
p 
20
09
